<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>financerelease.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
PRESS RELEASE                           LIFE SCIENCES RESEARCH, INC.
                                        (Pink Sheets: LSRI)

                                        PO Box 2360
                                        Mettlers Road
                                        East Millstone, NJ 08875-2360

                                        For Further Information:
                                        Richard Michaelson
                                        Phone:   US: (732) 649-9961
                                        e-mail: LifeSciencesResearch@LSRinc.net

March 2, 2006
                     LSR ANNOUNCES NEW $70 MILLION FINANCING
             Proceeds to be used in part to redeem outstanding bonds


East Millstone,  New Jersey, March 2, 2006 - Life Sciences Research,  Inc. (Pink
Sheets: LSRI) announced today that it has secured new long term financing of $70
million.  Net proceeds of the loan of approximately  $63 million will be used to
redeem the $46.2 million  outstanding  principal  amount of HIH 7.5% Convertible
Capital  Bonds,  which were due to mature in  September  2006,  and for  general
corporate purposes.

The loan matures on March 1, 2011 and bears an interest rate of 8.25% over LIBOR
(which may be reduced to 8.00%  over  LIBOR  upon the  Company  meeting  certain
financial tests). The loan has standard financial and business covenants.

Life  Sciences  Research,  Inc.  is  a  global  contract  research  organization
providing product development  services to the pharmaceutical,  agrochemical and
biotechnology  industries.  LSR brings  leading  technology  and  capability  to
support its clients in  non-clinical  safety  testing of new  compounds in early
stage development and assessment.  The purpose of this work is to identify risks
to humans, animals or the environment resulting from the use or manufacture of a
wide  range of  chemicals  which  are  essential  components  of LSR's  clients'
products.   The  Company's   services  are  designed  to  meet  the   regulatory
requirements of governments  around the world. LSR operates research  facilities
in the United States (the Princeton  Research Center, New Jersey) and the United
Kingdom (Huntingdon and Eye, England).

This announcement  contains statements that may be forward-looking as defined by
the Private Securities Litigation Reform Act of 1995. These statements are based
largely  on  LSR's  expectations  and are  subject  to a  number  of  risks  and
uncertainties,  certain of which are beyond our control, as more fully described
in the Company's SEC filings,  including its Form 10-K for the fiscal year ended
December 31, 2004, as filed with the US Securities and Exchange Commission.

                                   --- end ---

</TEXT>
</DOCUMENT>